KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Payables (2016 - 2025)

Historic Payables for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $939.0 million.

  • Regeneron Pharmaceuticals' Payables rose 1893.6% to $939.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $939.0 million, marking a year-over-year increase of 1893.6%. This contributed to the annual value of $939.0 million for FY2025, which is 1893.6% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Payables is $939.0 million, which was up 1893.6% from $903.8 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Payables' 5-year high stood at $939.0 million during Q4 2025, with a 5-year trough of $427.0 million in Q3 2021.
  • Moreover, its 5-year median value for Payables was $562.8 million (2021), whereas its average is $611.1 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Payables plummeted by 7468.22% in 2021, and later soared by 8174.14% in 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Payables (Quarter) stood at $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then rose by 2.95% to $606.6 million in 2023, then soared by 30.15% to $789.5 million in 2024, then increased by 18.94% to $939.0 million in 2025.
  • Its Payables was $939.0 million in Q4 2025, compared to $903.8 million in Q3 2025 and $723.9 million in Q2 2025.